[go: up one dir, main page]

AU2003289716A1 - Molecules for diagnostics and therapeutics - Google Patents

Molecules for diagnostics and therapeutics

Info

Publication number
AU2003289716A1
AU2003289716A1 AU2003289716A AU2003289716A AU2003289716A1 AU 2003289716 A1 AU2003289716 A1 AU 2003289716A1 AU 2003289716 A AU2003289716 A AU 2003289716A AU 2003289716 A AU2003289716 A AU 2003289716A AU 2003289716 A1 AU2003289716 A1 AU 2003289716A1
Authority
AU
Australia
Prior art keywords
therapeutics
diagnostics
molecules
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003289716A
Other versions
AU2003289716A8 (en
Inventor
Christina M. Altus
Scott B. Anderson
Alan P. Au
Steven C. Banville
John L. Blanchard
Christopher M. Bruns
Angelo M. Delegeane
Linda V. Elder
Jr. Edward H. Gerstin
Darryl Gietzen
Toinette A. Harthshorne
Bonnie L. Hurwitz
Jennifer L. Jackson
Edward S. Kirton
Mary KWONG
Robert E. Lagace
Yan Ma
Mirjana M. Marjanovic
Elizabeth M. Mooney
Iqbal S. Panesar
Scott R. Panzer
Srikanth PATURY
Careyna H. Peralta
Steven J. Pitts
Jennifer L. Policky
Thirupathi P. Reddy
Pierre RIOUX
Jeanette P. Schmidt
Edward J. Shen
Fan Shen
Xiaobing SHI
Peter A. Spiro
Kristian A. Stevens
Elizabeth A. Stewart
Laura L. Stuve
Charlyn J. Suarez
Martin T. Suchorolski
Ursula A. Vitt
Xinhao Wang
James WINGROVE
Rachel J. Wright
Mingham C. Wu
Yuming Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Incyte Corp
Original Assignee
Incyte Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Incyte Corp filed Critical Incyte Corp
Publication of AU2003289716A1 publication Critical patent/AU2003289716A1/en
Publication of AU2003289716A8 publication Critical patent/AU2003289716A8/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
AU2003289716A 2002-09-12 2003-09-12 Molecules for diagnostics and therapeutics Abandoned AU2003289716A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41026002P 2002-09-12 2002-09-12
US41025902P 2002-09-12 2002-09-12
US60/410,260 2002-09-12
US60/410,259 2002-09-12
PCT/US2003/028227 WO2004023973A2 (en) 2002-09-12 2003-09-12 Molecules for diagnostics and therapeutics

Publications (2)

Publication Number Publication Date
AU2003289716A1 true AU2003289716A1 (en) 2004-04-30
AU2003289716A8 AU2003289716A8 (en) 2004-04-30

Family

ID=31997928

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003289716A Abandoned AU2003289716A1 (en) 2002-09-12 2003-09-12 Molecules for diagnostics and therapeutics

Country Status (2)

Country Link
AU (1) AU2003289716A1 (en)
WO (1) WO2004023973A2 (en)

Families Citing this family (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030114410A1 (en) 2000-08-08 2003-06-19 Technion Research And Development Foundation Ltd. Pharmaceutical compositions and methods useful for modulating angiogenesis and inhibiting metastasis and tumor fibrosis
WO2003054141A2 (en) * 2001-10-22 2003-07-03 Children's Medical Center Corporation Sperm-specific cation channel, catsper2, and uses therefor
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
AU2003302774A1 (en) 2002-12-06 2004-06-30 Diadexus, Inc. Compositions, splice variants and methods relating to ovarian specific genes and proteins
US8871709B2 (en) * 2003-02-05 2014-10-28 Queensland University of Technolgy Synthetic chimeric proteins comprising epidermal growth factor and vitronectin
US7344860B2 (en) 2003-04-03 2008-03-18 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
WO2004094623A2 (en) * 2003-04-04 2004-11-04 Incyte Corporation Cell adhesion and extracellular matrix proteins
EP2332982A1 (en) * 2003-05-14 2011-06-15 Sumitomo Chemical Co., Ltd. Liver X receptor alpha splicing mutant protein, gene thereof and utilization of the same
CN1894409A (en) * 2003-08-18 2007-01-10 惠氏公司 Human LXR alpha variants
US9408891B2 (en) 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
CA2545718C (en) * 2003-11-12 2016-05-10 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
ES2364335T3 (en) * 2003-12-24 2011-08-31 G2 Inflammation Pty Ltd TRANSGENIC NON-HUMAN MAMMER THAT INCLUDES A POLINUCLEOTIDE CODIFYING HUMAN OR HUMANIZED C5AR.
WO2005076012A2 (en) * 2004-01-30 2005-08-18 Five Prime Therapeutics, Inc. Novel splice variants and methods of use thereof
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
US8124730B1 (en) 2004-04-02 2012-02-28 Bristol-Myers Squibb Company Polynucleotide encoding a novel human P2X7 splice variant, HBMYP2X7v
EP1586587A1 (en) * 2004-04-16 2005-10-19 Exonhit Therapeutics SA Compositions and methods for detecting angiogenesis
WO2005112970A2 (en) 2004-05-12 2005-12-01 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat infections
EP1794314A2 (en) * 2004-07-23 2007-06-13 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with vasoactive intestinal peptide receptor 1 (vpac1)
WO2006008008A2 (en) * 2004-07-23 2006-01-26 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with hepatocyte nuclear factor 4, alpha (hnf4a)
EP2316927B1 (en) * 2004-10-21 2014-11-05 Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Kaspp (lrrk2) gene, its production and use for the detection and treatment of neurodegenerative disorders
US7947436B2 (en) 2004-12-13 2011-05-24 Alethia Biotherapeutics Inc. Polynucleotides and polypeptide sequences involved in the process of bone remodeling
KR100664587B1 (en) * 2004-12-22 2007-01-04 김현기 Human cancer suppressor gene, protein encoded thereby, expression vector comprising the same and cells transformed with the vector
EP1891234B1 (en) 2005-06-01 2014-12-10 Evotec International GmbH Use of slc39a12 proteins as target in diagnosis and drug screening in alzheimer's disease
EP1739092A1 (en) * 2005-06-28 2007-01-03 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Peptidic antagonists of class III semaphorins/neuropilins complexes
US9957569B2 (en) 2005-09-12 2018-05-01 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
CA2622295C (en) 2005-09-12 2019-01-15 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
AU2012244391B2 (en) * 2005-12-20 2014-09-11 Sbi Biotech Co., Ltd. Anti-ILT7 antibody
RS53752B1 (en) * 2005-12-20 2015-06-30 Sbi Biotech Co. Ltd. ANTITELO PROTIV ILT7
AU2014265023A1 (en) * 2005-12-20 2014-12-04 Sbi Biotech Co, Ltd. Anti-ILT7 Antibody
US8383799B2 (en) 2006-01-20 2013-02-26 Cell Signaling Technology, Inc. Translocation and mutant ROS kinase in human non-small cell lung carcinoma
HUE039085T2 (en) * 2006-01-20 2018-12-28 Cell Signaling Technology Inc Translocation and mutant ROS kinase in human non-small cell lung carcinoma
WO2007089659A2 (en) * 2006-01-26 2007-08-09 Caprion Pharmaceutical, Inc. Tat-039 and methods of assessing and treating cancer
US20070192886A1 (en) * 2006-01-30 2007-08-16 Daniel Chelsky TAT-044 and methods of assessing and treating cancer
WO2007089793A2 (en) * 2006-01-31 2007-08-09 Caprion Pharmaceuticals, Inc. Tat-041 and methods of assessing and treating cancer
CN101443030A (en) 2006-03-15 2009-05-27 布赖汉姆妇女医院有限公司 Use of gelsolin for diagnosis and treatment of inflammatory diseases
ES2651619T3 (en) 2006-03-15 2018-01-29 The Brigham And Women's Hospital, Inc. Use of gelsolin to treat multiple sclerosis and diagnose neurological diseases
US7452985B2 (en) * 2006-08-17 2008-11-18 Visgeneer, Inc. Human Ron-related gene variant associated with cancers
US9689879B2 (en) 2006-08-21 2017-06-27 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
US9513296B2 (en) 2006-08-21 2016-12-06 Eidgenoessische Technische Hochschule Zurich Specific and high affinity binding proteins comprising modified SH3 domains of Fyn kinase
EP1892248A1 (en) 2006-08-21 2008-02-27 Eidgenössische Technische Hochschule Zürich Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase
US8119772B2 (en) * 2006-09-29 2012-02-21 California Institute Of Technology MART-1 T cell receptors
CA2668800A1 (en) 2006-11-08 2008-06-05 Macrogenics West, Inc. Tes7 and antibodies that bind thereto
ATE533861T1 (en) 2007-07-06 2011-12-15 Univ Michigan MIPOL1-ETV1 GENE ARRANGEMENTS
EP2537529B1 (en) 2007-08-02 2018-10-17 Gilead Biologics, Inc. Loxl2 inhibitory antibodies and uses thereof
US8106037B2 (en) 2007-08-03 2012-01-31 The Brigham And Women's Hospital, Inc. Identification and treatment of estrogen responsive prostate tumors
CA2705486C (en) 2007-11-19 2019-04-02 Celera Corporation Lung cancer markers and uses thereof
CA2711691A1 (en) * 2008-01-07 2009-07-16 Patrys Limited Barb4 target, antibody designated barb4, barb4 related antibodies, and methods of making and using same
PL2708603T3 (en) 2008-01-25 2017-12-29 Beth Israel Deaconess Medical Ct Inc Diagnostic and therapeutic uses of gelsolin in renal failure
WO2009131605A2 (en) * 2008-01-28 2009-10-29 Thomas Jefferson University Fusion partner cell line for preparation of hybrid cells expressing human antibodies
AU2013202410B2 (en) * 2008-07-16 2014-10-09 Institute For Research In Biomedicine Human cytomegalovirus neautralizing antibodies and use thereof
ES2613841T3 (en) 2008-07-16 2017-05-26 Medical And Biological Laboratories Co., Ltd. Human anti-CLCP1 antibody and use thereof
WO2010033294A1 (en) 2008-09-22 2010-03-25 Cedars-Sinai Medical Center Short-form human md-2 as a negative regulator of toll-like receptor 4 signaling
US9512196B2 (en) 2008-09-22 2016-12-06 Cedars-Sinai Medical Center Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
EP2382466B1 (en) * 2008-12-30 2016-03-09 Children's Medical Center Corporation Method of predicting acute appendicitis
US9107935B2 (en) 2009-01-06 2015-08-18 Gilead Biologics, Inc. Chemotherapeutic methods and compositions
WO2010107825A2 (en) 2009-03-16 2010-09-23 Pangu Biopharma Limited Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
JP4495776B1 (en) * 2009-07-30 2010-07-07 日本製薬株式会社 Fusion protein
JP2013502226A (en) 2009-08-21 2013-01-24 ギリアド バイオロジクス，インク． Catalytic domain derived from lysyl oxidase and LOXL2
CN102712953A (en) 2009-09-17 2012-10-03 密歇根大学董事会 Recurrent gene fusions in prostate cancer
CN102741294A (en) 2009-11-30 2012-10-17 霍夫曼-拉罗奇有限公司 Antibodies for the treatment and diagnosis of tumors expressing SLC34A2 (TAT211=SEQID2)
UA109888C2 (en) 2009-12-07 2015-10-26 ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES
US8828395B2 (en) 2009-12-11 2014-09-09 Atyr Pharma, Inc. Antibodies that bind tyrosyl-tRNA synthetases
EP2939689B1 (en) 2009-12-11 2017-09-13 aTyr Pharma, Inc. Glutaminyl tRNA synthetases for use in the treatment of inflammatory disorders
NZ602892A (en) 2010-04-13 2014-08-29 Celldex Therapeutics Inc Antibodies that bind human cd27 and uses thereof
AU2011248357B2 (en) * 2010-05-03 2017-02-23 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of seryl-tRNA synthetases
WO2012021249A2 (en) 2010-07-12 2012-02-16 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of histidyl-trna synthetases
WO2012027611A2 (en) 2010-08-25 2012-03-01 Atyr Pharma, Inc. INNOVATIVE DISCOVERY OF THERAPEUTIC, DIAGNOSTIC, AND ANTIBODY COMPOSITIONS RELATED TO PROTEIN FRAGMENTS OF TYROSYL-tRNA SYNTHETASES
EP2621944A2 (en) * 2010-09-30 2013-08-07 Institut National De La Sante Et De La Recherche Medicale (Inserm) Chimeric peptides including a penetrating peptide and a binding domain of pp2a catalytic subunit to caspase-9
US8945556B2 (en) 2010-11-19 2015-02-03 The Regents Of The University Of Michigan RAF gene fusions
WO2013022982A2 (en) 2011-08-09 2013-02-14 Atyr Pharma, Inc. Pegylated tyrosyl-trna synthetase polypeptides
EP2771689A4 (en) * 2011-10-26 2015-06-03 Nuclea Biotechnologies Inc PEPTIDES USP2A AND ANTIBODIES
US8835387B2 (en) 2012-02-16 2014-09-16 Atyr Pharma, Inc. Histidyl-tRNA synthetases for treating autoimmune and inflammatory diseases
EP2845862B1 (en) 2012-05-01 2018-11-21 FUJIFILM Corporation Method for incubating pluripotent stem cells and polypeptide to be used therefor
CN105007939B (en) * 2012-10-05 2018-10-19 卡德门企业有限公司 Human anti-VEGFR-2/KDR antibody
BR112015021399A2 (en) 2013-03-14 2017-07-18 Bayer Healthcare Llc heparin-complexed antithrombin beta monoclonal antibodies
JP6397479B2 (en) 2013-03-15 2018-09-26 エータイアー ファーマ， インコーポレイテッド Histidyl-tRNA synthetase Fc conjugate
JP6854246B2 (en) 2015-06-08 2021-04-07 アーケア ダイアグノスティクス リミテッド How to analyze urine sample
ES2911415T3 (en) 2015-06-08 2022-05-19 Arquer Diagnostics Ltd Methods and kits
EP3331356A4 (en) * 2015-08-04 2019-04-10 New York University FRAGMENTS AND DERIVATIVES OF PROGRANULIN (PGRN) FOR THE TREATMENT OR RELIEF OF LYSOSOMAL DISEASES
CA3017197A1 (en) 2016-03-10 2017-09-14 Viela Bio, Inc. Ilt7 binding molecules and methods of using the same
CR20180531A (en) * 2016-04-08 2019-06-13 Immunocore Ltd T-cell RECEIVERS
US20240002459A1 (en) * 2016-07-14 2024-01-04 Emory University Granulin Compositions and Uses Related Thereto
CA3060514A1 (en) 2017-04-20 2018-10-25 Atyr Pharma, Inc. Compositions and methods for treating lung inflammation
IL315224A (en) 2017-05-08 2024-10-01 Gritstone Bio Inc Alphavirus neoantigen vectors
CA3066569A1 (en) 2017-06-07 2018-12-13 Regeneron Pharmaceuticals, Inc. Compositions and methods for internalizing enzymes
TWI820034B (en) * 2017-07-31 2023-11-01 香港商映像生物有限公司 Cellular models of and therapies for ocular diseases
MX2020007077A (en) 2018-01-04 2020-10-28 Iconic Therapeutics Inc ANTI-TISSUE FACTOR ANTIBODIES, ANTIBODY-DRUG CONJUGATES AND RELATED METHODS.
JP7779653B2 (en) 2018-02-07 2025-12-03 リジェネロン・ファーマシューティカルズ・インコーポレイテッド Methods and compositions for therapeutic protein delivery
GB201803010D0 (en) * 2018-02-26 2018-04-11 Royal Holloway & Bedford New College Neurodegenerative disorders
CN112292185B (en) 2018-04-17 2025-07-29 塞德斯医疗公司 Anti-CD 27 and anti-PD-L1 antibodies and bispecific constructs
KR20250140631A (en) 2018-05-17 2025-09-25 리제너론 파마슈티칼스 인코포레이티드 Anti-cd63 antibodies, conjugates, and uses thereof
IL288283B2 (en) 2019-05-30 2025-05-01 Gritstone Bio Inc Modified adenoviruses
CN111859913B (en) * 2020-06-12 2024-04-12 北京百度网讯科技有限公司 Processing method and device of wind control characteristic factors, electronic equipment and storage medium
EP4192496A4 (en) 2020-08-06 2025-01-01 Gritstone bio, Inc. MULTIPLE EPITOPE VACCINE CASSETTES
WO2022213083A2 (en) * 2021-03-30 2022-10-06 Board Of Regents, The University Of Texas System Citrullinated proteins as biomarkers and therapy targets for cancer
TW202417476A (en) 2022-08-18 2024-05-01 英商英美偌科有限公司 T cell receptors and fusion proteins thereof
WO2024163607A2 (en) * 2023-02-02 2024-08-08 Board Of Regents, The University Of Texas System T-cell receptors targeting egfr and methods of use thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020119452A1 (en) * 2000-01-18 2002-08-29 Phippard Deborah J. Osteoarthritis tissue derived nucleic acids, polypeptides, vectors, and cells

Also Published As

Publication number Publication date
WO2004023973A3 (en) 2004-09-23
AU2003289716A8 (en) 2004-04-30
WO2004023973A2 (en) 2004-03-25

Similar Documents

Publication Publication Date Title
AU2003289716A1 (en) Molecules for diagnostics and therapeutics
AU2002344208A1 (en) Molecules for diagnostics and therapeutics
AU2003900780A0 (en) Analysis system and procedure
AU2003284238A1 (en) Indentation hardness test system
AU2003288210A1 (en) Process meter
AUPS078002A0 (en) Dnazyme therapeutics
AU2003278578A1 (en) Molecules and methods using same for measuring non-transferrin bound iron
AU2003251766A1 (en) Partially ester-exchanged sipm and process therewith
AU2003222120A1 (en) Oxon process
AU2003210518A1 (en) Molecules for diagnostics and therapeutics
AU2003288387A1 (en) Droplet - deposition related methods and apparatus
EP1572168A3 (en) Anti-infarction molecules
AUPS187002A0 (en) Condition-specific molecules and uses therefor
AU2003205627A1 (en) Diagnostics and therapeutics for diseases associated with gpr72
AU2002950242A0 (en) Screws
AU2003301457A1 (en) Bioweapon-detecting fibrous-network products and methods for making same
AU2003241466A1 (en) Surface-covering system and methods for making and using the same
AU2002305913A1 (en) Molecules for diagnostics and therapeutics
AU2003242205A1 (en) Key unit and method for manufacturing the same
AU4018201A (en) Molecules for diagnostics and therapeutics
AU2001241754A1 (en) Molecules for diagnostics and therapeutics
AU2001286964A1 (en) Molecules for diagnostics and therapeutics
AU2003231740A1 (en) Compositions and methods for diagnostics and therapeutics for hydrocephalus
AUPS161602A0 (en) Novel molecules and uses therefor
AU2003283606A1 (en) Psoriasis diagnostics and therapeutics

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase